HISTOGENICS CORPORATION ANNOUNCES ADJOURNMENT OF ITS SPECIAL MEETING TO THURSDAY, SEPTEMBER 26, 2019

HISTOGENICS CORPORATION ANNOUNCES ADJOURNMENT

OF ITS SPECIAL MEETING TO THURSDAY, SEPTEMBER 26, 2019

BOSTON, Mass. September 12, 2019 Histogenics Corporation (Nasdaq: HSGX) (the Company or

Histogenics ) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the Special Meeting ) held on September 12, 2019, at 9:00 a.m., local time, until

Thursday, September 26, 2019 at 9:00 a.m., local time, at which time Histogenics stockholders will vote on the proposals to be considered at the Special Meeting (subject to any potential additional adjournments), including a proposals

necessary to approve Histogenics proposed merger with Ocugen, Inc. ( Ocugen ) as described in the definitive prospectus/proxy statement/information statement, which is included as part of Histogenics Registration Statement on

Form S-4, as amended (File No. 333-232147). The Special Meeting will still be held at the offices of Gunderson Dettmer Stough Villeneuve Franklin &

Hachigian, LLP located at One Marina Park Drive, Suite 900, Boston, MA 02210. The Special Meeting was adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.

At the Special Meeting, stockholders of Histogenics will be asked to approve and adopt that certain Agreement and Plan of Merger and Reorganization,

dated as of April 5, 2019, as amended (the Merger Agreement ), by and among the Company, its wholly-owned subsidiary, Restore Merger Sub, Inc. ( Merger Sub ) and Ocugen, which provides for the merger (the

Merger ) of Merger Sub with and into Ocugen, including the proposed Merger, and such other proposals as disclosed in the definitive prospectus/proxy statement/information statement relating to the Special Meeting. The full meeting agenda

and each of the proposals being voted upon at the Special Meeting are detailed in the definitive prospectus/proxy statement/information statement, which is included as part of the Registration Statement on Form

S-4, as amended (File No. 333-232147), of Histogenics. Stockholders of record at the close of business on July 15, 2019 are entitled to receive notice of the

Special Meeting and to vote the shares of common stock of Histogenics owned by them at the Special Meeting.

Additional Information about the Merger

and Where to Find It

In connection with the proposed Merger, Histogenics has filed with the Securities and Exchange Commission (the SEC ) a

registration statement on Form S-4 that contains a prospectus/proxy statement/information statement and other relevant documents concerning the proposed business combination. The registration statement on

Form S-4 was declared effective by the SEC on August 6, 2019. Histogenics mailed the prospectus/proxy statement/information statement to its stockholders beginning on or around August 12, 2019.

Investors and security holders of Histogenics and Ocugen are urged to read the definitive proxy statement/prospectus/information statement and other materials filed or that will be filed with the SEC because they contain or will contain important

information about Histogenics, Ocugen and the Merger. The proxy statement/prospectus/information statement and other relevant materials, and any other documents filed by Histogenics with the SEC, may be obtained free of charge at the SEC web

site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Histogenics by directing a written request to: Histogenics Corporation, c/o Gunderson Dettmer, One Marina Park Drive,

Suite 900, Boston, MA 02210, Attention: HSGX Secretary.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor

shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection

with the proposed Merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

directors and executive officers and Ocugen and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Histogenics in connection with the proposed transaction. Information

regarding the special interests of these directors and executive officers in the

proposed Merger are included in the definitive proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of Histogenics is also included

in Histogenics Annual Report on Form 10-K for the year ended December 31, 2018. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Secretary of Histogenics

at the address described above.

Forward-Looking Statements

This Press Release contains forward-looking statements based upon Histogenics current expectations. Forward-looking statements involve risks and

uncertainties, and include, but are not limited to, statements about the structure, timing and completion of the proposed Merger, the financing contemplated to occur prior to the Merger and the sale of certain assets of Histogenics following

the Merger; expectations regarding Nasdaq s delisting and hearing processes, Histogenics prospects to regain compliance with Nasdaq s continuing listing standards and remain listed on The Nasdaq Capital Market; the combined

company s listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company, including potential dilution resulting from the financing contemplated to occur prior to the Merger or any

future debt or equity financings; the expected executive officers and directors of the combined company; the combined company s expected cash position at the closing of the proposed Merger; the future operations of the combined company; the

nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; the executive and board structure of the combined company; the location of the

combined company s corporate headquarters; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; Ocugen having sufficient

resources to advance its pipeline; the expected charges and related cash expenditures that Histogenics expects to incur; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those

anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the risk that the conditions to the closing of the proposed Merger are not satisfied, including the failure to

timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Histogenics and Ocugen to consummate the proposed Merger and the

financing contemplated to occur prior to the Merger; (iii) risks related to Histogenics ability to manage its operating expenses and its expenses associated with the proposed Merger pending closing; (iv) risks related to the failure or

delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of the financing contemplated to occur prior to the Merger, Histogenics

stockholders and Ocugen stockholders could own less of the combined company than is currently anticipated; (vi) risks related to the market price of Histogenics common stock relative to the exchange ratio; (vii) unexpected costs, charges

or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger or the financing contemplated to occur prior to the Merger;

(ix) the uncertainties associated with the clinical development and regulatory approval of Ocugen s product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (x) risks related to

the inability of the combined company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results for product candidates and

unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties

involved in successfully bringing product candidates to market; (xiii) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger or the financing contemplated to occur prior to the Merger,

including with respect to future financial and operating results; and (xiv) risks related to unanticipated charges not currently contemplated that may occur as a result of Histogenics prior workforce reductions, including that the

workforce reduction charges, costs and expenditures may be greater than currently anticipated. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and

uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled Risk Factors in Histogenics Annual Report on Form 10-K for the year ended December 31, 2018 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, each as filed with the SEC, and in other filings

that Histogenics makes and will make with the SEC in connection with the proposed Merger, including the proxy statement/prospectus/information statement described above under Where You Can Find More Information. You

should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Histogenics

expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or

circumstances on which any such statements are based.

Source: Histogenics Corporation